Literature DB >> 23393675

Nephropathy in diabetes.

Bancha Satirapoj1.   

Abstract

The most common cause of end stage renal disease (ESRD) requiring dialysis is diabetes. Both environmental and genetic factors have been postulated as the risk factors of Diabetic Nephropathy (DN). Hyperglycemia-induced metabolic and hemodynamic pathways are recognized to be mediators of kidney injury. Multiple biochemical pathways have been postulated that explain how hyperglycemia causes tissue damage: Non-enzymatic glycation that generates advanced glycation end products, activation of protein kinase C, acceleration of the polyol pathway and oxidative stress. Three major histologic pathological changes occur in DN: Mesangial expansion, GBM thickening, and glomerular sclerosis. It now seems clear in targeting a therapeutic regimen to achieve blood glucose, blood pressure and proteunuric goals, dietary protein and salt restriction, weight reduction, aggressive lipid lowering, smoking cessation and exercise. Multiple intensive interventions reduce cardiovascular events as well as nephropathy by about half when compared with conventional multifactorial treatment.

Entities:  

Mesh:

Year:  2012        PMID: 23393675     DOI: 10.1007/978-1-4614-5441-0_11

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  21 in total

1.  Down-regulation of miR-23a inhibits high glucose-induced EMT and renal fibrogenesis by up-regulation of SnoN.

Authors:  Haiping Xu; Fuyun Sun; Xiuli Li; Lina Sun
Journal:  Hum Cell       Date:  2017-07-13       Impact factor: 4.174

Review 2.  Diabetic Kidney Disease in Older People with Type 2 Diabetes Mellitus: Improving Prevention and Treatment Options.

Authors:  Ahmed H Abdelhafiz
Journal:  Drugs Aging       Date:  2020-08       Impact factor: 3.923

3.  Suppression of Type-II Diabetes with Dyslipidemia and Nephropathy by Peels of Musa cavendish Fruit.

Authors:  Vijay Navghare; Shashikant Dhawale
Journal:  Indian J Clin Biochem       Date:  2016-02-03

Review 4.  Prevalence and Management of Diabetic Nephropathy in Western Countries.

Authors:  Bancha Satirapoj; Sharon G Adler
Journal:  Kidney Dis (Basel)       Date:  2015-05-01

5.  Ameliorative effect of rubiadin-loaded nanocarriers in STZ-NA-induced diabetic nephropathy in rats: formulation optimization, molecular docking, and in vivo biological evaluation.

Authors:  Mohd Mujeeb; Abdul Ahad; Mohd Aqil; Waseem Ahmad Siddiqui; Abul Kalam Najmi; Mymoona Akhtar; Apeksha Shrivastava; Abdul Qadir; Thasleem Moolakkadath
Journal:  Drug Deliv Transl Res       Date:  2021-05-19       Impact factor: 4.617

6.  Periostin as a tissue and urinary biomarker of renal injury in type 2 diabetes mellitus.

Authors:  Bancha Satirapoj; Surat Tassanasorn; Mongkon Charoenpitakchai; Ouppatham Supasyndh
Journal:  PLoS One       Date:  2015-04-17       Impact factor: 3.240

7.  Oxymatrine Inhibits Renal Tubular EMT Induced by High Glucose via Upregulation of SnoN and Inhibition of TGF-β1/Smad Signaling Pathway.

Authors:  Lirong Liu; Yuanyuan Wang; Rui Yan; Shuang Li; Mingjun Shi; Ying Xiao; Bing Guo
Journal:  PLoS One       Date:  2016-03-24       Impact factor: 3.240

8.  High glucose induces trafficking of prorenin receptor and stimulates profibrotic factors in the collecting duct.

Authors:  Venkateswara R Gogulamudi; Danielle Y Arita; Camille R T Bourgeois; Justine Jorgensen; Jing He; William C Wimley; Ryosuke Satou; Alexis A Gonzalez; Minolfa C Prieto
Journal:  Sci Rep       Date:  2021-07-05       Impact factor: 4.379

9.  The proteasome inhibitor, MG132, attenuates diabetic nephropathy by inhibiting SnoN degradation in vivo and in vitro.

Authors:  Wei Huang; Chen Yang; Qinling Nan; Chenlin Gao; Hong Feng; Fang Gou; Guo Chen; Zhihong Zhang; Pijun Yan; Juan Peng; Yong Xu
Journal:  Biomed Res Int       Date:  2014-06-09       Impact factor: 3.411

10.  Effect of sulodexide on urinary biomarkers of kidney injury in normoalbuminuric type 2 diabetes: a randomized controlled trial.

Authors:  Bancha Satirapoj; Wisit Kaewput; Ouppatham Supasyndh; Prajej Ruangkanchanasetr
Journal:  J Diabetes Res       Date:  2015-03-31       Impact factor: 4.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.